Montpark (montelukast) trial results by Prof Per Svenningsson

We are delighted to share this recording, the 1st of a series of 4, that one of the world's leading PD Charities, Cure Parkinson's, hosted recently in Central London.
Cure Parkinson's Linked Clinical Trials (iLCT) programme aims to repurpose existing drugs that have shown promise in other diseases and test their effectiveness in people with Parkinson’s. Now in its 12th year, the iLCT initiative was the subject of their latest research update meeting focusing on advancements within the programme. Cure Parkinson's featured two key-note presentations, the 1st being Professor Per Svenningsson presenting on the upcoming montelukast phase 2 clinical trial testing an anti-inflammatory drug.
Cure Parkinson's have a simple goal;- to ensure that everything they do is to move closer to finding new treatments to slow, stop or reverse the progression of Parkinson’s.
More can be found out here on their website where your donations and your involvement in research will lead to the breakthrough that we all want to see.
cureparkinsons...

[@xcicilyx]

very encouraging

[@jnerses]

Is it possible to get this medication now?

[@nosilverbullet4pd998]

This is an existing anti inflammatory, anti asthma drug but this is a phase 2 trial to see if it can be repurposed for Parkinson’s. It is therefore too early to use it for Parkinson’s, but it is worth keeping an eye on this.